Eli Lilly and Co. was one of the supporters that helped raise $139 million for Jaguar Gene Therapy in a Series B funding round. Jaguar is developing preclinical gene therapies that target galactosemia, type 1 diabetes and gene-linked autism.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.